BVF Partners LP recently announced the acquisition of new stake in Aravive Inc. (NASDAQ:ARAV). This fresh investment now brings its stake to 8.00% valued currently at $6.32 million.
With over 0.17 million Aravive Inc. (ARAV) shares trading Tuesday and a closing price of $1.71 on the day, the dollar volume was approximately $0.28 million. The shares have shown a positive half year performance of 98.61% and its price on 01/24/23 lost nearly -2.84%. Currently, there are 30.52M common shares owned by the public and among those 29.93M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for ARAV have a consensus price objective of $9.80. The analysts have set the share’s price value over the next 12 months at a high of $18.00 and a low of $2.00. The average price target is 82.55% above its recent price level and an upside to the estimated low will see the stock gain 14.5% over that period. But an upside of 90.5% will see the stock hit the forecast high price target while median target price for the stock is $10.00.
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 10 of these insider trades were purchases, accounting for 23,244,562 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Aravive Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.26 million shares of the company’s stock, all valued at over $0.34 million. Vanguard Extended Market Index Fu bought 302.0 shares to see its total holdings expand to 0.17 million shares valued at over $0.22 million and representing 0.28% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.12% of the shares outstanding.
However, the script later moved the day high at 1.8000, down -2.84%. The company’s stock has a 5-day price change of -0.58% and 107.27% over the past three months. ARAV shares are trading 29.55% year to date (YTD), with the 12-month market performance down to -23.32% lower. It has a 12-month low price of $0.58 and touched a high of $2.40 over the same period. ARAV has an average intraday trading volume of 648.40K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 11.22%, 14.73%, and 45.65% respectively.
Institutional ownership of Aravive Inc. (NASDAQ: ARAV) shares accounts for 6.70% of the company’s 30.52M shares outstanding. Mutual fund holders own 11.94%, while other institutional holders and individual stakeholders account for 51.15% and 1.08% respectively.
It has a market capitalization of $98.77M and a beta (3y monthly) value of 2.39. The earnings-per-share (ttm) stands at -$2.35. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.04% over the week and 8.65% over the month.
Analysts forecast that Aravive Inc. (ARAV) will achieve an EPS of -$0.64 for the current quarter, -$0.39 for the next quarter and -$1.62 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.69 while analysts give the company a high EPS estimate of -$0.54. Comparatively, EPS for the current quarter was -$0.53 a year ago. Earnings per share for the fiscal year are expected to decrease by -0.80%, and 38.50% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Aravive Inc. (ARAV) as a “Strong Buy” at a consensus score of 1.70. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ARAV, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on June 03, 2022, with the firm’s price target at $15. BTIG Research coverage for the Aravive Inc. (ARAV) stock in a research note released on March 08, 2021 offered a Buy rating with a price target of $26. Robert W. Baird on their part issued Outperform rating on December 02, 2019.